Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396353 | 1.00 | PTGS2 (0.35) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL15135362 | 1.00 | PTGS2 (0.35) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL15135361 | 0.88 | MAPT (0.34) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL396352 | 0.88 | MAPT (0.34) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL16914737 | 0.88 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL3400690 | 0.83 | ALDH1A1 (0.39) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL13001173 | 0.80 | MAPT (0.30) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL3400688 | 0.80 | MAPT (0.30) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL13000821 | 0.80 | MAPT (0.30) | PTGS2PTGS1MAPTCRHBPCRHR2 | |
| SCHEMBL3404736 | 0.80 | MAPT (0.30) | PTGS2PTGS1MAPTCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274279-B1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2011-04-21 | — | — | US | disclosed |
| EP-2274279-A1 | NITRIC OXIDE DONATING PROSTAMIDES | Nicox S.A. (FR) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009136281-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | PTGIS, PTGIR, NOS2 | PTGS2 6/4885PTGS1 4/4885MAPT 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.